Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Advanced Dermatology, P.C. adds ten new Nevisense installations to its extensive practice network.

Stockholm, Sweden and New York, US, - December 16, 2021 - SciBase Holding AB  ("SciBase") [STO:SCIB], a leader of augmented intelligence-based solutions for skin disorders, announced today that it has received an order of ten additional Nevisense systems and electrodes valued at approximately KUSD 100 from Advanced Dermatology, P.C. ("AdvDermPC") in New York City.AdvDermPC is one of the largest dermatology groups in the New York City tri-state area with 59 practices.  This order brings the total number of AdvDermPC practices utilizing Nevisense to seventeen.

Peab acquires property in Borås

Peab has signed a contract with Corem for the acquisition of the mall Knallerian with four properties in the commercial area Knalleland in Borås for an underlying property value of SEK 110 million. There is a positive zoning plan decision concerning development of the area.Peab has acquired the mall Knallerian with four properties and a total area of 15,165 m2 in the commercial area Knalleland. The leasable space is close to 23,000 m2 and currently has around 40 tenants. There is a positive zoning plan decision concerning development of the area and Borås has marked it as a focus zone

Murgröna Holding completes the recommended public offer to the shareholders of ICA Gruppen and extends the acceptance period

THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO ANY JURISDICTION (INCLUDING WITHOUT LIMITATION AUSTRALIA, CANADA, CHINA, HONG KONG, JAPAN, MEXICO, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR SWITZERLAND) WHERE THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE IN CONFLICT WITH ANY APPLICABLE LAWS OR REGULATIONS. THE OFFER IS NOT BEING MADE TO (AND ACCEPTANCE FORMS WILL NOT BE ACCEPTED FROM OR ON BEHALF OF) PERSONS WHOSE PARTICIPATION IN THE OFFER WOULD REQUIRE THAT ANY OFFER DOCUMENTS ARE PREPARED, FILINGS ARE EFFECTUATED OR OTHER MEASURES

BICO has entered into an agreement to acquire Biosero, a leading software provider for automated workflows and laboratory connectivity

The addition of Biosero’s software capabilities brings immediate synergies and will allow BICO to offer its customers fully automated and connected workflow solutions using the combination of technologies and products from current portfolio companies together with Biosero’s software solutions. In the short to mid-term, these cross-business synergies have the potential to unlock large orders related to automated workflows. BICO will also invest 20 MUSD over a three-year period to further accelerate Biosero’s commercial agenda to expand to new geographical markets and to fully monetize on

BerGenBio announces exclusive in-license of key intellectual property rights from UT Southwestern Medical Center

In-Licensing further strengthens intellectual property estate for the treatment of Non-Small Cell Cancer (NSCLC) patients with STK11 mutations  Bergen, Norway, 16 December 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announced  today the licensing of certain intellectual property from the UT Southwestern Medical Center.  The exclusive license to intellectual property generated by researchers at UT Southwestern Medical Center supports the Company's existing IP position underlying use

Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer

Oslo, Norway, 16 December 2021 Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces the appointment of Sandra Jonsson, PhD, MBA as Chief Operating Officer. Dr Jonsson will start on 10 January 2022 and takes over from Marco Renoldi, MD, who is retiring from the role but will remain as a consultant to the company. Dr Jonsson is a results-driven international Life Science executive, with >15 years of cross-functional experience in global pharmaceutical and biotechnology companies.

Assemblin signs national service agreement for Vattenfall’s nuclear power plants

Assemblin is delighted to announce the renewal of its framework agreement to supply maintenance, servicing and installation services to Forsmarks Kraftgrupp AB and Ringhals AB.The nationwide agreement covers electrical, instrument and mechanical maintenance for the period 2022–2024. The agreement will meet Vattenfall’s need for maintenance services at its nuclear power plants in Forsmark and Ringhals, as well as other nuclear-related operations in the Nordic region, such as the decommissioning of nuclear power plants, management of radioactive waste and spent nuclear fuel and new

Green Landscaping Group continues its establishment in Finland through the acquisition of the landscaping company Viherpojat Oy

16 December 2021, 07:00 CET Green Landscaping Group AB (publ) has acquired Viherpojat Oy with a turnover of approximately EUR 4 million. The acquisition is the second in Finland and another step on the way to establish a platform of entrepreneurial quality companies in Finland.Viherpojat is a reputable company with a long history in the landscaping industry in the Helsinki area and delivers projects to construction companies, the public sector and housing companies. The company has sales of approximately EUR 4 million and 25 employees. - We are pleased that Viherpojat joins the group

Lehto Group Plc: Mr Tero Karislahti appointed as Executive Vice President of the Housing Service Area

Lehto Group PlcStock exchange release16 December 2021 at 8.00 (a.m.)Mr Tero Karislahti, 39, has been appointed as Executive Vice President of the Housing Service Area and as a member of Lehto Group’s Executive Board as of 10 June 2022. Karislahti has a master's degree in engineering and 18 years of work experience in various positions at the construction group YIT. Since 2015, Karislahti has worked in management positions in housing construction, including as regional director.“With Tero Karislahti, the company will obtain more excellence in the field of housing construction. He

Aquaporin wins a pilot for an energy efficient solution to China’s leachate overflow

The Danish water technology company Aquaporin has won a strategic order in China to help a landfill meet the country’s strict discharge limits by treating leachate more efficiently.Managing leachate discharge in China In the first half of 2022, the landfill will receive an advanced containerized pilot system developed by Aquaporin in collaboration with Gradiant Environmental Technology to provide a sustainable and economical solution for treating landfill leachate. Aquaporin is currently involved in similar pilot projects in Southern China and Europe with the purpose of testing the

For IBS, specific diets are less important than expected

Many IBS sufferers avoid certain types of food and often exclude gluten. However, a large new study from Chalmers University of Technology and Uppsala University, Sweden, does not show a relationship between high intake of gluten and increased IBS symptoms. The researchers did find that a certain type of carbohydrate called ‘fodmaps’ can aggravate intestinal problems, however, the overall results indicate that they also have less influence than previously thought.“IBS is a very complex disease involving many factors, but our results indicate that the effects of specific diets

Embracer Group successfully completed a directed issue of 69,000,000 new B shares raising proceeds of roughly SEK 6 billion

INSIDE INFORMATION: Embracer Group AB (the "Company" or “Embracer Group”) has, as announced in its press release on December 15, 2021, carried out an issue of 69,000,000 new B shares directed to Swedish and international institutional investors, resolved upon by the Board of Directors based on the authorization from the annual general meeting on September 16, 2021 (the "Share Issue"). The subscription price in the Share Issue is SEK 87 per B share and has been determined through an accelerated book-building procedure led by Nordea Bank Abp, filial i Sverige, HSBC Continental Europe,

Getinge reinvents office work in the South Asia Pacific region

As a trailblazer within remote working, the global medtech company Getinge’s implementation of a long-term flexible workplace approach in the South Asia-Pacific (SAPAC) region has been a success. The acceptance rate among employees is over 90 per cent in the markets that have already implemented the concept.What started as a health and safety measurement in the early days of the COVID-19 outbreak, has turned into an established way of working in Getinge’s worldwide organization, with the objective to offer employees with position eligible for remote work a possibility to choose flexibility.

The exercise price for the warrants of series TO1 in GET Group AB (publ) has been determined to approximately SEK 0.104

GET Group AB (publ) (”GET Group” or the ”Company”) completed during December 2020 an rights issue of units consisting of one (1) new share and one (1) free of charge warrant of series TO1. In total, 41,008,175 warrants of series TO1 was issued. Each warrant entitles the holder to subscribe for one (1) new share in the Company during the period from and including 16 December 2021 to and including 30 December 2021. The exercise price per share is to be determined to 70 percent of the volume-weighted average price in the Company’s share on NGM Nordic SME during the measurement period from and

Braeburn receives new Complete Response Letter for Brixadi in the US

Lund, Sweden — 15 December 2021 — Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its updated New Drug Application (NDA) for Brixadi™ (buprenorphine) extended-release injections for the treatment of opioid use disorder. The CRL is a result of continued quality related deficiencies at Braeburn’s US based third party manufacturer, identified by the FDA during a pre-approval inspection. “We are very disappointed to learn of the new Complete Response Letter for Brixadi

Checkin.com successfully completes a directed share issue raising proceeds of approximately SEK 56 million

Checkin.com Group AB (STO:CHECK) (“Checkin.com Group” or the “Company”) has, as announced in its press release on December 15, 2021, carried out an issue of 1 million new shares directed to institutional investors, resolved upon by the Board of Directors based on the authorization from the annual general meeting on April 26, 2021 (the “Directed Share Issue”). The subscription price in the Directed Share Issue was SEK 56 per share and has been determined through an accelerated book-building procedure led by Carnegie Investment Bank AB (publ) and Erik Penser Bank AB (jointly referred to as the "

New research article demonstrates the potential for lab-on-chip catalysis using Attana technology

A recent article published in RSC Advances (Royal Society of Chemistry) illustrates how Attana gold coated surfaces functionalized with a combination of polyethyleneimine and palladium nanoparticles have been used as efficient catalysts and the potential for using this approach in lab-on-a-chip-based synthesis applications using the Attana Quartz Crystal Microbalance (QCM) system.Attana technology has been applied by the team of Prof Ian Nicholls at Linnaeus University, in their development of a flow microreactor for catalyzes of a series of Suzuki reactions. The recently published RSC

Nordea Bank Abp: Repurchase of own shares on 15.12.2021

Nordea Bank AbpStock exchange release – Changes in company’s own shares15.12.2021 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 15.12.2021 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number of Weighted average Total cost, EUR* **venue (MIC shares price / share, EUR* Code) **XSTO 940,126 10.35 9,730,837.61XHEL 656,940 10.34 6,794,730.42CEUX 842,223 10.35 8,715,696.42AQEU 135,906 10.34

Intervacc comments on the trading halt of the company's share on Nasdaq First North

Stockholm, December 15, 2021 - Nasdaq Stockholm has decided to temporarily stop trading in Intervacc after a volatile trading session and a decline in the share price. The reason for the price decline is speculation in social media about the company's vaccine Strangvac, following the Medical Products Agency having published a so-called monograph on the vaccine. The Medical Products Agency states in the monograph: “Experience has shown that it is difficult to produce a vaccine against strangles that can effectively prevent horses from becoming infected, spreading infection and developing

Trading of own shares as part of employee’s savings scheme

SpareBank 1 SR-Bank ASA has on 15 December 2021 purchased 30 000 own shares at an average price of NOK 123,8868 Total holdings of own shares after the purchase is 71 273 shares. The shares were acquired as part of SpareBank 1 SR-Bank’s savings scheme for employees. For more information about the saving scheme reference is made to the stock exchange notice dated 10 December 2020, and the stock exchange notice dated 29 April 2021. As part of SpareBank 1 SR-Bank ASA savings scheme the company will acquire additional shares, up to a number of 75 000, within 31 December 2021.

Commencement of new plan periods in long-term incentive plans targeted to Metso Outotec management and key employees

Metso Outotec Corporation’s stock exchange release on December 15, 2021, at 7:10 p.m. EETThe Board of Directors of Metso Outotec Corporation has approved the commencement of a new plan period 2022-2024 in the following share-based long-term incentive programs of the Company: The Performance Share Plan (also "PSP") and the Restricted Share Plan (also "RSP"). Metso Outotec originally announced the establishment of the PSP and the RSP structure on July 1, 2020. PSP 2022-2024 PSP 2022-2024 is subject to achieving performance targets set by the Board of Directors, measured over a three-

NOTE presents new financial targets and sustainability goals

Today NOTE presents new financial targets and sustainability goals for the company. At tomorrow's Capital Markets Day, NOTE's Group Management will provide further insight into the company's operations, strategy, new financial targets and sustainability goals. NOTE's new financial target is that by 2025 at the latest: · Reach a sales level of at least SEK 5 billion.This should essentially be achieved through high organic growth complemented by carefully selected acquisitions. · Reach an operating margin of at least 10%. Other financial targets regarding capital structure and

Terveystalo Plc: SHARE REPURCHASE 15.12.2021

Terveystalo Plc ANNOUNCEMENT  15.12.2021 Terveystalo Plc: SHARE REPURCHASE 15.12.2021 In the Helsinki Stock Exchange Trade date           15.12.2021Bourse trade         BuyShare                  TTALOAmount             21 748 SharesAverage price/ share    11,1237 EURTotal cost            241 918,23 EUR Terveystalo Plc now holds a total of 1 507 017 sharesincluding the shares repurchased on 15.12.2021 On behalf of Terveystalo Plc Nordea Bank Oyj Janne

Targovax awarded NOK 9.8m research grant by the Research Council of Norway towards the TG mutant RAS program

Oslo, Norway, 15 December 2021 - Targovax ASA (OSE: TRVX) a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the Research Council of Norway has awarded Targovax a NOK 9.8m research grant towards product and clinical development for the TG mutant KRAS cancer vaccine program.The Research Council of Norway has awarded the grant within the category “Innovation Project for the Industrial Sector”. Project title: “Development of targeted therapies for mutant RAS cancers”Awarded by: The Research Council of Norway

There are no items matching the current filter
There are no more items matching the current filter
Back to top